[1] SORIA JC, OHE Y, VANSTEENKISTE J, et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J].N Engl J Med, 2018, 378(2):113. doi: 10.1056/NEJMoa1713137
[2] PANCEWICZ-WOJTKIEWICZ J, BERNATOWICZ PL.The effect of afatinib treatment in non-small cell lung cancer cells[J].Anticancer Res, 2017, 37(7):3543.
[3] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018:globocan estimate of incidence and mortality world wide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2018, 68(6):394. doi: 10.3322/caac.21492
[4] CASCONE T, GOLD KA, SWISHER SG, et al.Induction cisplatin docetaxel followed by surgery and erlotinib in non-small cell lung cancer[J].Ann Thorac, 2018, 105(2):418. doi: 10.1016/j.athoracsur.2017.08.052
[5] 岳兴家, 许加华, 张洪洋, 等.多西他赛联合阿帕替尼在非鳞癌非小细胞肺癌二线治疗中的疗效[J].中国老年学杂志, 2019, 39(8):1849.
[6] HEIST RS, GUARINO MJ, MASTERS G, et al.Therapy of advanced non-small-cell lung cancer with an SN-38-Anti-Trop-2 drug conjugate, sacituzumab govitecan[J].J Clin Oncol, 2017, 35(24):2790. doi: 10.1200/JCO.2016.72.1894
[7] 牛东升, 孙丽敏.放疗联合阿帕替尼、多西他赛治疗晚期肺癌的临床疗效研究[J].实用癌症杂志, 2019, 34(12):1991.
[8] ASBURY RF, LIPSITZ S, GRAHAM D, et al.Treatment of squamous cell esophageal cancer with topotecan:an Eastern Cooperative Oncology Group Study (E2293)[J].Am J Clin Oncol, 2000, 23(1):45. doi: 10.1097/00000421-200002000-00013
[9] TSUCHIDA Y, THERASSE P.Response evaluation criteria in solid tumors (RECIST):New guidelines[J].Med Pediatr Oncol, 2001, 37(1):1. doi: 10.1002/mpo.1154
[10] BASCH E, IASONOS A, MCDONOUGH T, et al.Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events:results of a questionnaire-based study[J].Lancet Oncol, 2006, 7(11):903. doi: 10.1016/S1470-2045(06)70910-X
[11] 赵论, 张浩然, 石默晗, 等.安罗替尼联合多西他赛二线治疗无驱动基因晚期非小细胞肺癌的临床疗效观察[J].中华全科医学, 2020, 18(4):537.
[12] 吴军, 戴明.多西他赛联合阿帕替尼二线治疗非鳞癌非小细胞肺癌的疗效观察[J].中国肿瘤临床与康复, 2020, 27(3):307.
[13] TABCHI S, KOURIE HR, KATTAN J.Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer:a new therapeutic strategy[J].Invest New Drugs, 2016, 34(6):794. doi: 10.1007/s10637-016-0383-2
[14] ECKERT MA, SANTIAGO-MEDINA M, LWIN TM, et al.ADAM12 induction by TWIST1 promotes tumor invasion and metastasis via regulation of invadopodia and focal adhesions[J].J Cell Sci, 2017, 130(12):2036. doi: 10.1242/jcs.198200
[15] ANTONIA SJ, VILLEGAS A, DANIEL D, et al.Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer[J].N Engl J Me, 2017, 377(20):1919. doi: 10.1056/NEJMoa1709937
[16] 刘洁, 王秀问.培美曲塞/多西他赛三线化疗晚期非小细胞肺癌预后因素分析[J].中国医师进修杂志, 2018, 41(8):717.
[17] 斯晓燕, 王汉萍, 张晓彤, 等.安罗替尼治疗晚期非小细胞肺癌16例临床分析[J].中华内科杂志, 2018, 57(11):830.
[18] 刘楠, 吴秀伟, 李烦繁, 等.安罗替尼三线及以上治疗晚期非小细胞肺癌近期疗效和生命质量分析[J].国际肿瘤学杂志, 2019, 46(3):147.
[19] 闻艺璇, 梁利军, 陈婷, 等.安罗替尼临床应用研究进展[J].中华肿瘤防治杂志, 2019, 26(14):979.
[20] 纪春东, 于秀芹, 赖永新, 等.培美曲塞和多西他赛分别同步放化疗治疗局部晚期非小细胞肺癌的临床疗效[J].实用癌症杂志, 2016, 31(7):1140.
[21] 郭运杰, 井小会.多西他赛联合阿帕替尼二线治疗非鳞癌非小细胞肺癌的有效性及安全性分析[J].中国肿瘤临床, 2017, 44(11):544.
[22] 陈玉, 李强, 张聪, 等.消癌平注射液辅助TP方案化疗对晚期NSCLC患者免疫状态、不良反应及生命质量的影响[J].国际肿瘤学杂志, 2019, 46(1):17.